In the first head-to-head trial of biologic treatments for inflammatory bowel disease, vedolizumab (Entyvio, Takeda) was nearly 50% more effective than adalimumab (Humira, AbbVie) in inducing clinical and mucosal remission in patients with moderate to severe ulcerative colitis.
The findings, which researchers presented at the 2019 meeting of the European Crohn’s and Colitis Organisation (oral presentation 34), and again at the 2019 Digestive Disease Week, provide important evidence to